Polycyclo Ring System Having The Five-membered Hetero Ring As One Of The Cyclos Patents (Class 514/410)
  • Publication number: 20080234260
    Abstract: A compound of the formula II wherein one of R1 and R2 is halo and the other is H or halo; R3 is C1-C4 straight or branched chain, optionally fluorinated, alkyl; R4 is H; or R3 together with R4 and the adjoining backbone carbon defines: a spiro-C5-C7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4 alkyl or C1-C4 haloalkyl; or optionally bridged with a methylene group; or a C4-C6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(?O)2; where Ra is H, C1-C4 alkyl or CH3C(?O); R5 is independently selected from H or methyl; E is —C(?O)—, —S(?O)m—, —NR5S(?O)m—, —NR5C(?O)—, —OC(?O)—, R6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or heterocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.
    Type: Application
    Filed: January 6, 2005
    Publication date: September 25, 2008
    Inventors: Magnus Nilsson, Xiao-Xiong Zhou, Lourdes Oden, Bjorn Classon, Rolf Noren, Urszula Grabowska, Philip Jackson, Philip Fallon, Andrew Carr, Mark Liley, Matt Tozer, Tony Johnson, Victor Diaz, Laia Crespo, Jussi Kangasmetsa, Thierry Bonnaud
  • Publication number: 20080220058
    Abstract: A method and composition for improving human hair, having a composition of neutraceuticals that include Eclipta, chlorophyll, and an absorption enhancer, in which the absorption enhancer is selected from the group consisting of bioperine and phosphatidyl choline and Eclipta is included in an amount between 0.1 and 60 parts admixed by weight of the composition. The method and composition can be administered: (a) sublingually, having a solute, preferably ethanol, and preferably in the range between 0.1% and 30% by volume; (b) orally by encapsulation in a gelatinous capsule; and/or (c) by chewable mixture having a gum material and/or a flavor.
    Type: Application
    Filed: March 9, 2007
    Publication date: September 11, 2008
    Inventor: Robert McCarthy
  • Patent number: 7423056
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: September 9, 2008
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, David C. Bom, Michael J. Robarge
  • Publication number: 20080213219
    Abstract: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: March 19, 2008
    Publication date: September 4, 2008
    Inventor: Jerome B. Zeldis
  • Publication number: 20080206222
    Abstract: A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one kind of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and an organic compound with which the fullerene or derivative has been modified or clathrated. The composition is reduced in side effects, has the high ability to eliminate free radicals in the body, and further has excellent preparation stability.
    Type: Application
    Filed: August 5, 2005
    Publication date: August 28, 2008
    Inventors: Nobuhiko Miwa, Shinobu Ito, Kenji Matsubayashi
  • Publication number: 20080206227
    Abstract: Methods and compositions are provided for the treatment of diseases such as exudative macular degeneration, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, retinal neovascularization, iris neovascularization, corneal neovascularization, ocular tumors, and other disorders of the eye, cancer, and inflammatory disorders. The method involves administering a conjugate, referred to as fVIIPD, containing a photosensitizer and a targeting molecule such as factor VII (“fVII”), fVIIa, or modified fVII, which binds with high affinity and specificity to tissue factor (TF). TF is more highly expressed, abnormally expressed or specifically expressed on endothelial cells lining the luminal surface of pathological neovasculature, than on normal vasculature, thus providing a specific and accessible therapeutic target.
    Type: Application
    Filed: April 21, 2008
    Publication date: August 28, 2008
    Inventors: Alan Garen, Zhiwei Hu
  • Patent number: 7414069
    Abstract: Three new alkaloids, Hirsutellones A, B, and C, are produced in cultures of fungus such as Hirsutella nivea strain BCC 2594 and Trichoderma sp. strain BCC 7579. The Hirsutellones exhibited potent growth inhibitory activity against Mycobacterium tuberculosis (H37Ra strain) with an MIC value of 0.78 ?g/ml, while showing weak or no cytotoxicity to mammalian cells. Therefore, Hirsutellones and pharmaceutical compositions containing Hirsutellones may be useful for the treatment of tuberculosis. Also described herein are methods of isolating the Hirsutellones.
    Type: Grant
    Filed: November 21, 2005
    Date of Patent: August 19, 2008
    Assignee: National Center for Genetic Engineering & Biotechnology, National Science & Technology Development Agency
    Inventors: Masahiko Isaka, Nigel Leslie Hywel-Jones, Sayanh Somrithipol, Kanyawim Kirtikara, Prasit Palittapongarnpim, Yodhathai Thebtaranonth
  • Publication number: 20080195032
    Abstract: A new treatment regime is presenter using a low concentration formulation at a low dosage of hydrophobic photosensitizers (PS) that shows improved pharmacokinetics and an effective method for photodynamic therapy (“PDT”). The new formulation has better pharmacological effect compared to standard photosensitizer formulation with standard dosage. It was found that PDT treatments using the disclosed low concentration formulations provide for more accurate, more efficient and more convenient dosing. It was found that the inventive formulation; (1) reduces the time for a therapeutically effective level of photosensitizer to accumulate in diseased tissue; and, (2) reduces the time for achieving a sufficient ratio of photosensitizer in diseased tissue vs. healthy tissue. As a result, the formulation of the invention reduces the time interval between PS application/administration and irradiation (the drug-light interval or “DLI”) and can provide for a “same day” PDT treatment option.
    Type: Application
    Filed: April 4, 2008
    Publication date: August 14, 2008
    Inventors: Nikolay Nifantiev, Volker Albrecht
  • Patent number: 7410978
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: August 12, 2008
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Publication number: 20080153891
    Abstract: The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.
    Type: Application
    Filed: December 6, 2007
    Publication date: June 26, 2008
    Applicant: The Arizona Board of Regents
    Inventors: Robert T. DORR, David S. Alberts, Evan M. Hersh
  • Patent number: 7390821
    Abstract: The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis.
    Type: Grant
    Filed: March 1, 2006
    Date of Patent: June 24, 2008
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John Cooke, Christopher Heeschen, Michael Weis
  • Publication number: 20080146556
    Abstract: The present invention relates to a method of treating cancer using PARP inhibitors as radio-sensitization agents of tumors. Specifically the present invention relates to a method of radio-sensitization of tumors using a compound of Formula (I) or a pharmaceutically acceptable salt form thereof. The present invention also relates to a pharmaceutical compositions of PARP inhibitors for radiosensitizing tumors.
    Type: Application
    Filed: November 20, 2007
    Publication date: June 19, 2008
    Applicant: Cephalon, Inc.
    Inventors: James L. Diebold, Robert L. Hudkins, Sheila J. Miknyoczki, Bruce Ruggeri
  • Patent number: 7388024
    Abstract: The present invention provides indeno[2,1a]indene and isoindolo[2,1-a]indole derivatives of the Formula I, its salts and its stereoisomers, wherein X, R1, R2, R3, R4, R6, R7, R8, R9, R11, R12, R13 and R14 are as described in the specification. The invention also provides a method to prepare the compound of formula I, pharmaceutical composition containing such compounds, and method to manufacture a medicament. These compounds are useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardio vascular diseases and cancer.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: June 17, 2008
    Assignee: Suven Life Sciences Limited
    Inventors: Jasti Venkateswarlu, Satya Nirogi Ramakrishna Venkata, Sastri Kambhampati Rama, Shreekrishna Shirsath Vikas, Kandikere Vishwottam Nagaraj
  • Patent number: 7375215
    Abstract: A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or acylated poly(alkylene oxide) or to a hydroxy group of a link residue itself carrying a residue of such poly(alkylene oxide).
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: May 20, 2008
    Assignee: Bioscience Technology Investment Holdings Limited
    Inventors: Paul Bradley, Mehar Manku
  • Patent number: 7371742
    Abstract: This invention relates to porphyrin compounds used to destroy or impair the functioning of a target biological material in photodynamic therapy, in particular against virus, tumoral cells, bacteria, tumorous tissues. The invention also relates to compositions containing such compounds and to a method in vitro to photosensitize detroy or impair the functioning of such target biological material.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: May 13, 2008
    Assignees: Institut Curie, Centre National de la Recherche Scientifique (CNRS)
    Inventors: David Grierson, Philippe Maillard, Bernard Loock, Telmo Figueiredo, Alain Croisy, Danielle Carrez
  • Publication number: 20080103114
    Abstract: The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3?-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with an inhibitor of a membrane bound Epidermal Growth Factor Receptor (EGFR) inhibitors, to treat conditions associated with exposure to RSV.
    Type: Application
    Filed: December 30, 2005
    Publication date: May 1, 2008
    Inventor: Michael A. Zeligs
  • Patent number: 7365209
    Abstract: Nitrogen heterocycle biaryls having a carboxylate terminus are useful for treating endometriosis, osteoporosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity. Compounds of formula: are disclosed.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: April 29, 2008
    Assignee: Pharmacopeia, Inc.
    Inventors: Jeffrey John Letourneau, Vidyahar Paradkar, Michael H. J. Ohlmeyer, Lawrence W. Dillard, John J. Baldwin, Christopher Mark Riviello, Angela Wong, Yaing Rong
  • Publication number: 20080096923
    Abstract: The present invention relates to a method for treating one or more diabetic microvascular complications in a patient in need of said treatment comprising: (a) diagnosing the severity of at least three different microvascular complications in said patient by calculating a diabetes microvascular complications score with a diabetes microvascular complications scoring tool; and (b) administering to said patient in need thereof a therapeutic amount of a compound selected from the group consisting of ruboxistaurin, enzastaurin, PKC 412, candesartan cilexetil, fidarestat, lidorestat, pyridoxamine and pegaptanib, or a pharmaceutically acceptable salt thereof, and ranibizumab; in an amount that is effective in treating one or more diabetic microvascular complications in said diabetic patient.
    Type: Application
    Filed: July 13, 2005
    Publication date: April 24, 2008
    Inventor: Aniz Girach
  • Publication number: 20080096857
    Abstract: The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to affected skin and subsequent exposure of that skin to energy of a wavelength capable of activating the photosensitizer.
    Type: Application
    Filed: February 8, 2005
    Publication date: April 24, 2008
    Applicant: QLT Inc.
    Inventors: Alain H. Curaudeau, Herma C. Neyndorff, Jing-Song Tao, Julia G. Levy, David W.C. Hunt, Morgan Chun Lam, Patrick Mark Curry, Valery Rubinchik
  • Patent number: 7354947
    Abstract: Isaothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof having the general formula: and pharmaceutically acceptable salts thereof, wherein R0 is —CH2—, —SO—, —O—, —SO2—, or —S—; compositions comprising the iazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof; and methods for treating or preventing a disorder alleviated by inhibiting Jun N-terminal kinase (JNK) by administering the isaothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof are described herein.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: April 8, 2008
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Steven T. Sakata, Heather K. Raymon
  • Patent number: 7348361
    Abstract: The invention concerns a 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation useful for diagnosing and/or treating tissue and/or cell pathologies by local radiation exposure using radiation emitted by a light source energy followed, in the case diagnosis, by detection of fluorescent protoporphyrin IX (Pp1X). The E-ALA concentration in the solution is less than 1% and ranges between 0.01% and 0.5%. The low E-ALA concentration in the solution increases Pp1X synthesis and homogenises its distribution in the cell layers while highly reducing the secondary toxicity for the treated cells.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: March 25, 2008
    Assignee: Ecole Polytechnique Federale de Lausanne
    Inventors: Alexandre Marti, Norbert Lange, Matthieu Zellweger, Georges Wagnieres, Hubert Van Den Bergh, Patrice Jichlinski, Pavel Kucera
  • Patent number: 7348425
    Abstract: Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: March 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thomas W. Hudyma, Xiaofan Zheng, Feng He, Min Ding, Carl P. Bergstrom, Piyasena Hewawasam, Scott W. Martin, Robert G. Gentles
  • Patent number: 7348352
    Abstract: New methods and compositions are disclosed that comprise the phytochemical Diindolylmethane, alone or in combination with immune potentiating steroids. These methods and compositions are utilized to treat subjects suffering from common cutaneous warts (verrucae) and Human Papilloma Virus (HPV) related conditions of the oropharynx, larynx, genitalia, and uterine cervix.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: March 25, 2008
    Assignee: Bioresponse L.L.C.
    Inventor: Michael A. Zeligs
  • Publication number: 20080069781
    Abstract: A method and composition is disclosed for treating oral diseases, including inflammatory periodontal disease, by utilizing photosensitizing compounds in long term effect or timed release formulations, including local highly concentrated formulations in biofilms on teeth and implants and oral wounds as well as periodontal pockets, and activating the photosensitizers with radiation to selectively destroy bacteria and other microbial bodies. Photosensitizers in a timed release formulation are released over a prolonged period of time. In a version, photosensitizers are housed within nanoparticles, and can be gradually released through biodegradation or periodically released by such processes as brushing, irradiation and chemically induced release. The formulation is applied to the oral cavity and allowed to settle on biofilms therein, in periodontal pockets formed by the disease, or coated at the desired sites.
    Type: Application
    Filed: September 19, 2006
    Publication date: March 20, 2008
    Inventor: Wolfgang Neuberger
  • Patent number: 7345034
    Abstract: Azacyclosteroid histamine-3 receptor ligands, pharmaceutical compositions comprising such compounds, and methods for using such compounds and compositions are described herein.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: March 18, 2008
    Assignee: Abbott Laboratories
    Inventors: Chen Zhao, Minghua Sun, Marlon D. Cowart, Youssef L. Bennani
  • Patent number: 7338973
    Abstract: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: March 4, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Zhihua Sui, Xuqing Zhang, Xiaojie Li
  • Publication number: 20080027090
    Abstract: The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.
    Type: Application
    Filed: July 26, 2007
    Publication date: January 31, 2008
    Applicant: WYETH
    Inventors: Matthew A. WILSON, Gregory S. WELMAKER, Eugene J. Trybulski, John A. BUTERA, Ronald L. MAGOLDA
  • Publication number: 20080021013
    Abstract: The invention provides a method for treating myeloproliferative disorders, myelodysplastic syndromes and other diseases, in which activation of JAK2 contributes to pathology, in a mammal comprising administering to the mammal an effective amount of a fused pyrrolocarbazole derivative wherein the fused pyrrolocarbazole derivative inhibits the activity of JAK2.
    Type: Application
    Filed: July 19, 2007
    Publication date: January 24, 2008
    Applicant: Cephalon, Inc.
    Inventors: Pawel Dobrzanski, Bruce A. Ruggeri
  • Patent number: 7317035
    Abstract: The present invention relates to novel tetracyclic arylcarbonyl indoles, their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, novel intermediates described herein and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel tetracyclic arylcarbonyl indoles of the general formula (I), their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, novel intermediates described herein and pharmaceutically acceptable compositions containing them.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: January 8, 2008
    Assignee: Suven Life Sciences Limited
    Inventors: Venkateswarlu Jasti, Venkata Satya Nirogi Ramakrishna, Rama Sastri Kambhampati, Srinivasa Reddy Battula, Venkata Satya Veerabhadra Vadlamudi Rao
  • Publication number: 20080004326
    Abstract: Method for production of indolocarbazoles by using rebeccamycin biosynthetic genes. The invention is based on utilization of rebeccamycin biosynthetic genes from Saccharothrix aerocolonigenes for production of indolocarbazoles in related microorganisms (Streptomyces spp.). Method includes the isolation of a DNA fragment from Saccharothrix aerocolonigenes ATCC39243 containing the rebeccamycin biosynthesis gene cluster and the expression of these genes in Streptomyces albus, achieving production of rebeccamycin and derivatives. The invention is suitable for use in the pharmaceutical field.
    Type: Application
    Filed: October 17, 2002
    Publication date: January 3, 2008
    Inventors: Cesar Sanchez Reillo, Alfredo Fernandez Brana, Jose Antonio Salas Fernandez, Carmen Mendez Fernandez
  • Publication number: 20070299046
    Abstract: Pheophorbide derivative compounds which can inhibit cell proliferation and angiogenesis in a light-independent manner are disclosed and claimed. Importantly, these compounds exhibit low toxicity, and are orally/subcutaneous/intravenously/transdermally/topically available, thus having value as new potential agents to treat cancer or diseases related to imbalance in cell proliferation and angiogenesis.
    Type: Application
    Filed: June 26, 2006
    Publication date: December 27, 2007
    Inventors: Mai Nguyen Brooks, Andrew John Norris
  • Patent number: 7312203
    Abstract: The present invention relates to 1-aza-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: December 25, 2007
    Assignee: GlaxoSmithKline istraziva{hacek over (c)}ki Centar Zagreb d.o.o.
    Inventors: Mladen Mercep, Milan Mesic, Dijana Pesic
  • Patent number: 7307095
    Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: December 11, 2007
    Assignee: IRM LLC
    Inventors: Hong Liu, David Tully, Phillip Alper, Robert Epple, Arnab Chatterjee, Michael Roberts
  • Patent number: 7307080
    Abstract: The disclosure relates to compounds, pharmaceutical compositions and methods for inhibiting PARP by use of the disclosed compositions.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: December 11, 2007
    Assignee: MGI GP, Inc.
    Inventors: Jia-He Li, Jie Zhang
  • Patent number: 7297711
    Abstract: The present invention relates to novel tetracyclic arylalkyl indoles, their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, novel intermediates described herein and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel tetracyclic arylalkyl of the general formula (I), their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, novel intermediates described herein and pharmaceutically acceptable compositions containing them. This invention also relates to process/es for preparing such compound/s of general formula (I), composition/s containing effective amount/s of such a compound and the use of such a compound/composition in therapy.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: November 20, 2007
    Assignee: Suven Life Sciences Limited
    Inventors: Venkateswarlu Jasti, Venkata Satya Nirogi Ramakrishna, Rama Sastri Kambhampati, Srinivasa Reddy Battula, Venkata Satya Veerabhadra Vadlamudi Rao
  • Patent number: 7294646
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: November 13, 2007
    Assignee: Merck & Co. Inc.
    Inventors: Maria L. Garcia, Michael A. Goetz, Gregory J. Kaczorowski, Owen B. McManus, Richard L. Monaghan, William R. Strohl, Jan S. Tkacz
  • Patent number: 7294647
    Abstract: Compounds having kappa opioid agonist activity, compositions containing them and 5 method of using them as analgesics and pruritic agents are provided. The compounds of formulae I, II, III and IV have the structure: wherein X, X4, X5, X7, X9; R1, R2, R3, R4; and Y, Z and n are as described in the specification.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: November 13, 2007
    Assignee: Adolor Corporation
    Inventors: Lawrence I. Kruse, An-Chih Chang, Diane L. DeHaven-Hudkins, John J. Farrar, Forrest Gaul, Virendra Kumar, Michael Anthony Marella, Alan L. Maycock, Wei Yuan Zhang
  • Publication number: 20070259939
    Abstract: Naltrexone has been used to fight existing infections, afflictions, and substance abuse. Embodiments of the current invention provide naltrexone as a preventative medicine taken daily, usually in the late evening for greater efficacy. It is taken in a low dose like a vitamin supplement and may prevent many diseases by stimulating the immune system. The increased endorphin levels resulting from the use of low dose naltrexone may also reduce the need for pain relief medications, plus counter tendencies toward experiencing undesirable moods, such as depression or anger. Increased feelings of well-being produced by naltrexone may also have far-reaching effects, as suggested by studies showing that people with positive attitudes recover more quickly from serious illnesses, for example. In another aspect of the invention, naltrexone may be used to prevent substance addiction before it ever starts, by blocking the internal positive response that normally results from the use of chemical substances.
    Type: Application
    Filed: October 18, 2006
    Publication date: November 8, 2007
    Applicant: ACCELERATED TECHNOLOGIES
    Inventor: Franklin Leroy Stebbing
  • Publication number: 20070237817
    Abstract: The present invention provides novel polymorphic and pseudopolymorphic forms of Trandolaprilat, including crystalline Trandolaprilat Form A, crystalline Trandolaprilat Form B, crystalline Trandolaprilat Form C, crystalline Trandolaprilat Form D, crystalline Trandolaprilat Form E, and mixtures thereof. The invention also provides novel methods for producing Trandolaprilat, pharmaceutically acceptable salts of Trandolaprilat, and polymorphic and pseudopolymorphic forms of Trandolaprilat, pharmaceutical compositions including one or more novel Trandolaprilat compounds and methods for treating high blood pressure and/or cardiac insufficiency using one or more novel Trandolaprilat compounds.
    Type: Application
    Filed: March 30, 2007
    Publication date: October 11, 2007
    Inventor: Thomas Bader
  • Publication number: 20070231375
    Abstract: The present invention relates to a liposome combination, which wrapped hydrophilic drugs in water layer and wrapped hydrophobic drugs in lipid bilayer; hydrophobic drugs are photosensitizers. Using light with appropriate wavelength to activate the photosensitizer in the hydrophobic layer can result in the production of singlet oxygen and the free radical, and cause the oxidizing and breaking of the carbon chain of the phospholipid, and influences the stability of the liposome and the releases of the drug. The singlet oxygen and the free radical will attack the cancer cells at the same time as a result of combining the photodynamic- and chemo-effects.
    Type: Application
    Filed: October 30, 2006
    Publication date: October 4, 2007
    Inventors: Tsuimin Tsai, Chin-Tin Chen, Ruey-Long Hong, Hong-Da Wu
  • Patent number: 7276494
    Abstract: A compound for use as a photosensitiser in PDT, in photochemical internalisation in the production of a cancer vaccine or in the diagnosis or detection of medical conditions, the compound having a photosensitising chromophoric system, a sulphonamido functionality and a carboxy functionality. The compounds used in the present invention are photosensitisers in PDT in vivo, and show phototoxic activity in vitro. The compounds are used to treat pre-cancerous conditions, cancer, ophthalmological disease, vascular problems, arteriosclerosis and restenosis and autoimmune diseases, skin diseases and other benign conditions, and for anti-microbial treatments.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: October 2, 2007
    Assignee: Photopharmica Limited
    Inventors: Stanley Beames Brown, Andrea Lucille Bell, John Griffiths, Jack Schofield
  • Publication number: 20070218465
    Abstract: Systems and methods for increasing protoporphyrin IX accumulation in a target cell population using aminolevulinate synthase variants. Aminolevulinic acid-mediated photodynamic therapy is a promising approach to treating dysplasic disorders such as cancer and atherosclerosis, but is limited by the lack of a means to deliver optimal quantities of aminolevulinic acid selectively to the target cells, and thereby ensure the best therapeutic response. The disclosed invention provides a means for enhancing the natural production of aminolevulinic acid selectively within target cells to levels predetermined to give an optimal therapeutic response, and is expected to lead to increased efficacy of treatment, possibly broadening the scope of diseases treatable by photodynamic therapy considerably. The disclosed invention is also amenable to patient specific therapy, meaning that a patient's target cells could be used to screen for the aminolevulinic acid delivery system most appropriate for the patient's needs.
    Type: Application
    Filed: June 29, 2006
    Publication date: September 20, 2007
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Gregory A. Hunter, Gloria C. Ferreira
  • Patent number: 7268155
    Abstract: Conjugate molecules which include photosensitizer compositions conjugated to non-antibody non-affinity pair targeting moieties and methods of making and using such conjugates are described.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: September 11, 2007
    Assignee: The General Hospital Corporation
    Inventors: Tayyaba Hasan, Michael R. Hamblin, Nikos Soukos
  • Patent number: 7267990
    Abstract: Porphyrins containing one or more neutral or negatively-charged, closo- or nido-carborane substituents are useful as chelators. The carbon-carbon bonds linking the boron-containing groups to the porphyrin ring make the compounds highly resistant to hydrolysis. These compounds have potential for use in selective binding to specific ligands. These compounds are highly stable, soluble in water and organic solvents, and have low toxicity.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: September 11, 2007
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventor: Maria da Graça Henriques Vicente
  • Patent number: 7265100
    Abstract: The present invention refers to a process for the separation of regioisomeric mixtures of metal phthalocyanines of formula (I), to the regioisomers obtained by this process, and their use as phototherapeutic and photodiagnostic agents
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: September 4, 2007
    Assignee: L. Molteni & C. Dei Fratelli Alitti Societa' di Esercizio S.p.A.
    Inventors: Gabrio Roncucci, Francesca Giuntini, Donata Dei, Maria Paola De Filippis, Paolo Sarri, Marco Possenti, Valentina Paschetta, Giacomo Chiti
  • Patent number: 7262215
    Abstract: This invention relates to N-carbacycle monosubstituted indolocarbazole compounds. Furthermore, this invention relates to medicaments comprising N-carbacycle monosubstituted indolocarbazoles compounds and the use of such compounds for treating non-insulin dependent diabetes mellitus, acute stroke and other neurotraumatic injuries, for treating diabetes mellitus, as a chemotherapeutic for the treatment of various malignant diseases, for treating diseases caused by malfunctioning of specific signaling pathways, and for treating neurodegenerative diseases such as for example Alzheimer's disease.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: August 28, 2007
    Assignee: NAD AG
    Inventors: Heidi Sahagun-Krause, Olivier Thillaye Du Boullay, Valerie Thillaye Du Boullay, Laura Casiraghi, Hans-Wolfgang Klafki, Pierfausto Seneci, Tobias Braxmeier, Silvia Müller, Wolfgang Fr{hacek over (o)}hner, Barbara Monse, Sandra Gordon, Hanno M. Roder
  • Publication number: 20070166369
    Abstract: Innovative non-surgical methods and compositions are provided for administering PDT to promote tissue regeneration or augmentation while minimizing scarring and risk of infection. Among several areas of application, is the treatment of acute and chronic wounds which have afflicted epidermal and connective tissue layers of the body. Another application area is as cosmetic surgery/treatments, including: reducing wrinkles, sulcus, scars (acne or traumatic caused), sequelae cellulite, as well as for other skin irregularities, to give a smoother skin surface. This invention consists of a collagen based or other suitable biodegradable supporting matrix which is embedded with a liposomal loaded photosensitizer. In one embodiment of this invention a liposomal formulated photosensitizer is first injected at the site followed by collagen implantation and PDT treatment. In another embodiment a liposomal formulated photosensitizer is incorporated in the collagen.
    Type: Application
    Filed: January 5, 2007
    Publication date: July 19, 2007
    Inventors: Wolfgang Neuberger, Volker Albrecht, Danilo Castro
  • Patent number: 7244841
    Abstract: A compound of formula I: wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4 and Z have meanings given in the description, and metallated forms of such compounds, which are useful in the treatment of medical conditions for which a photodynamic compound is indicated. Pharmaceutical formulations and methods of treatment of a medical condition for which a photodynamic agent is indicated are also disclosed. Sterilizing solutions comprising a compound of the invention, and the use thereof, are also disclosed.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: July 17, 2007
    Assignees: Destiny Pharma Limited, Solvias AG
    Inventors: William Love, Derek Brundish, William Rhys-Williams, Xiang Dong Feng, Benoit Pugin
  • Patent number: 7241796
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: July 10, 2007
    Assignee: Vertex Pharmaceuticals Inc.
    Inventors: Luc J. Farmer, Robert B. Perni, Janos Pitlik, John H. van Drie, Jr.
  • Patent number: 7241779
    Abstract: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: July 10, 2007
    Assignee: Cephalon, Inc.
    Inventors: Robert L. Hudkins, Allison L. Zulli, Dandu R. Reddy, Ming Tao, Theodore L. Underiner